[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368872-105":59,"doc-detail-368872-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","plasma-proteome-profiling-identifies-biomarkers-and-potential-drug-targets-for-non-small-cell-lung-cancer","Plasma Proteome Profiling Identifies Biomarkers and Potential Drug Targets for Non-Small Cell Lung Cancer","","Non-small cell lung cancer (NSCLC) requires expedited discovery of new drug targets. A proteome-wide Mendelian randomization analysis used genetic data for 4,853 plasma proteins. Lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC) summary data came from GWAS meta-analyses and FinnGen cohorts. Eight proteins showed causal links to NSCLC etiology, with specific associations distinguishing LUAD and LUSC risk. Findings were validated by Bayesian colocalization, SMR/HEIDI, bidirectional MR, scRNA-seq, GeneMANIA, GO, druggability, and PheWAS.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/plasma-proteome-profiling-identifies-biomarkers-and-potential-drug-targets-for-non-small-cell-lung-cancer/368872/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/plasma-proteome-profiling-identifies-biomarkers-and-potential-drug-targets-for-non-small-cell-lung-cancer/368872.png","ImageObject",300,407,{"name":92,"@type":93},"Ben ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What data and method were used to assess causal roles of plasma proteins in NSCLC?","Question",{"text":113,"@type":114},"Proteome-wide Mendelian randomization used pQTL summary statistics for 4,853 plasma proteins and extracted LUAD/LUSC data from GWAS meta-analyses and FinnGen cohorts.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which proteins were linked to increased risk of LUAD and LUSC?",{"text":118,"@type":114},"Five proteins were associated with increased LUAD risk when present at lower levels (CDH17, CXADR, FAM3D, POGLUT3, SFTPB), while two proteins showed increased LUAD risk with higher levels (CEACAM5, KLK1). For LUSC, higher CD14 levels were associated with elevated risk.",{"name":120,"@type":111,"acceptedAnswer":121},"How were the primary findings validated and did bidirectional MR show reverse causality?",{"text":122,"@type":114},"POGLUT3 and SFTPB were validated by Bayesian colocalization; one protein (SFTPB) was supported by SMR and HEIDI tests. Bidirectional MR found no reverse causality, and results were further checked using scRNA-seq, GeneMANIA, GO, druggability assessments, and PheWAS.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368872,1790378101,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336478951081,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Ivyspring  \nInternational Publisher  \nInternationalJournal of Medical Sciences  \n2025; 22(15): 4036-4048. doi: 10.7150/ijms.107109  \nResearch Paper  \nPlasma Proteome Profiling Identifies Biomarkers and Potential Drug Targets for Non-Small Cell Lung Cancer  \nMinghui Zhao1, Xiaoke Di1, Yucui Zhao2􀀍  \n1. Department of Radiation Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.  \n2. Department of Radiation Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.  \n􀀍 Corresponding author: Yucui Zhao, Department of Radiation Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, [China. Email: 2321130@zju.edu.cn](China. Email: 2321130@zju.edu.cn).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2024.11.07; Accepted: 2025.08.25; Published: 2025.09.12  \nAbstract  \nNon-small cell lung cancer (NSCLC), as one of the most commonly diagnosed cancers globally, requires expedited identification of new drug targets. We conducted proteome-wide MR using genetic data for 4,853 plasma proteins. Summary-level data on lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC) were extracted from GWAS meta-analyses (11,273 and 7,426 cases, respectively) and FinnGen cohort (1,590 and 1,510 cases, respectively). We genetically identified eight proteins with a causal role in the etiology of NSCLC. Lower levels of five proteins (CDH17, CXADR, FAM3D, POGLUT3, SFTPB) and higher levels of two proteins (CEACAM5, KLK1) were linked to increased LUAD risk, while higher CD14 levels were associated with elevated LUSC risk. Two proteins, POGLUT3 and SFTPB were validated through Bayesian colocalization. One protein SFTPB was identified using SMR and HEIDI tests. Bidirectional MR found no reverse causality. The primary findings were validated through scRNA-seq, GeneMANIA, GO analysis, druggability assessments and PheWAS analysis. These protein-coding genes are primarily expressed in epithelial cells, macrophages, monocytes, and endothelial cells. Furthermore, CEACAM5, KLK1, and CD14 correspond to existing drugs. These proteins may deepen our comprehension of the etiology and could serve as appealing novel biomarkers and drug targets for NSCLC management.  \nKeywords: proteome-wide Mendelian randomization, biomarker, drug target, non-small cell lung cancer.  \nIntroduction  \nLung cancer is the most frequently diagnosed malignancy globally and is the leading cause of cancer-related death. Annually, it is estimated that around 2.5 million new cases arise and over 1.8 million fatalities occur [1]. Approximately 80% to 85% of lung cancers are non-small cell lung cancer (NSCLC), with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) being the two predominant subtypes. LUAD has become the most common subtype, with incidence rates exceeding those of LUSC in recent years [2] . Most patients are diagnosed at an advanced stage, where curative treatment options are limited, resulting in a 5-year survival rate that hovers just above 20% [3, 4] . Therefore, there is an urgent need to discover sensitive and specific markers for the early prediction  \nof lung cancer to improve outcomes. Additionally, the development of novel therapeutic strategies is essential, either as standalone interventions or to enhance current prevention programs such as smoking cessation [5] .  \nProteins serve as the cornerstone of human metabolism, translating genomic information into the processes of growth, development, and homeostasis. The levels and characteristics of individual plasma proteins reflect a range of physiological or pathological states. Their accessibility via minimally invasive and ","cbCaivHyfBT96HBk","https://ap.wps.com/l/cbCaivHyfBT96HBk","pdf",1674615,13,"English","# Introduction\n## Background and Rationale\n## Mendelian Randomization Framework\n## Proteomics and Integrative Genomics Approaches\n# Study Design\n## Proteome-wide MR Using pQTL Summary Statistics","[{\"question\":\"What data and method were used to assess causal roles of plasma proteins in NSCLC?\",\"answer\":\"Proteome-wide Mendelian randomization used pQTL summary statistics for 4,853 plasma proteins and extracted LUAD/LUSC data from GWAS meta-analyses and FinnGen cohorts.\"},{\"question\":\"Which proteins were linked to increased risk of LUAD and LUSC?\",\"answer\":\"Five proteins were associated with increased LUAD risk when present at lower levels (CDH17, CXADR, FAM3D, POGLUT3, SFTPB), while two proteins showed increased LUAD risk with higher levels (CEACAM5, KLK1). For LUSC, higher CD14 levels were associated with elevated risk.\"},{\"question\":\"How were the primary findings validated and did bidirectional MR show reverse causality?\",\"answer\":\"POGLUT3 and SFTPB were validated by Bayesian colocalization; one protein (SFTPB) was supported by SMR and HEIDI tests. Bidirectional MR found no reverse causality, and results were further checked using scRNA-seq, GeneMANIA, GO, druggability assessments, and PheWAS.\"}]","Plasma Proteome Profiling Identifies Biomarkers and Potential Drug Targets for Non-Small Cell Lung Cancer | PDF",1790179019,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6487c04064c33104c1681991230fa7b.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c443cefb1b1fe728339d0eaed8cb34e4.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/411e153e369dfecae6afc5eaa30432fd.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b1782112fde1ccc4059d4d216150b1e8.webp",980,1268]